drugset / Trial / NCT02838121

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

NCT02838121

Phase 3 Completed 62 enrolled Mel Shiuann-Sheng Lee Novartis · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

Periprosthetic bone loss caused by stress-shielding effect, a phenomenon of bone atrophy under mechanical unloading after THR implantation, further compromises the longevity of implant. The prospective randomized study is aimed to investigate the periprosthetic bone loss after primary total hip replacements.

Timeline

Start
2009-12
Primary completion
2013-01
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications

No indication recorded.